'Show' and 'Shadow' Heparin Facilities Targeted in Pair of FDA Warning Letters

FDA issued heparin-related warning letters last month to two Chinese API suppliers - one for posing as a heparin API supplier, and the other for supplying adulterated heparin to the U.S. in violation of cGMP requirements